Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordan Krbec

Physician Assistant Round Rock, TX Physician Assistant

NPI 1093174278 CMS profile 10992220

2000 S Mays St Ste 300, Round Rock, TX 78664

Open in the dashboard

General payments

$8,903

432 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordan Krbec of Round Rock, TX is reported in the CMS Open Payments database as having received $8,903 across 432 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,743 139
2024 General $2,671 122
2023 General $3,131 153
2022 General $320 16
2021 General $37 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Krbec
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jordan Krbec were reported at $2,743. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jordan Krbec Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $37 $132 $37–$438 $132
2022 $320 $155 $48–$522 $149
2023 $3,131 $167 $52–$557 $160
2024 $2,671 $178 $55–$600 $164
2025 $2,743 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,476 84 payments
  2. AbbVie, Inc. $1,439 79 payments
  3. UCB, Inc. $961 42 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $870 32 payments
  5. AstraZeneca Pharmaceuticals LP $691 26 payments
  6. Novartis Pharmaceuticals Corporation $623 41 payments
  7. Janssen Biotech, Inc. $614 19 payments
  8. Pfizer Inc. $417 26 payments
  9. ANI Pharmaceuticals, Inc. $301 15 payments
  10. Mallinckrodt Hospital Products Inc. $278 10 payments
  11. Other $1,233 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,661 428 payments
  2. Education $242 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,008 48 payments
  2. COSENTYX $607 40 payments
  3. TREMFYA $576 17 payments
  4. Otezla $575 34 payments
  5. Cimzia $492 24 payments
  6. Bimzelx $469 18 payments
  7. OFEV $454 14 payments
  8. XELJANZ $417 26 payments
  9. Enbrel $415 26 payments
  10. TAVNEOS $410 23 payments
  11. Other $3,846 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,324

Median for Physician Assistant: 241

Drug cost

$1,483,931

Median for Physician Assistant: $4,110

Branded share of claims

21%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 66 $688,378
Otezla Apremilast Brand 44 $219,199
Rinvoq Upadacitinib Brand 25 $177,976
Orencia Clickject Abatacept Brand 26 $150,501
Cyltezo(Cf) Pen Adalimumab-Adbm Brand 14 $106,953
Enbrel Sureclick Etanercept Brand 13 $100,010
Hydroxychloroquine Sulfate Generic 256 $7,924
Methotrexate Methotrexate Sodium Brand 271 $5,408
Leflunomide Generic 117 $3,699
Celecoxib Generic 114 $3,347

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$38,032

Of which drugs: $1,082

Medicare patients

167

Average age 69

Services billed

1,171

128 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 35%
Diabetes 31%
Osteoporosis 29%
Ischemic heart disease 22%
Chronic kidney disease 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 45 277 $213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $301
$301 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $244
$244 — —
TREMFYA
  • Janssen Biotech, Inc. $206
$206 — —
RINVOQ
  • AbbVie, Inc. $201
$201 25 —
EVENITY
  • Amgen Inc. $159
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

432 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record